Josias Fantato De Pontes
Financieel Directeur/CFO bij SIGILON THERAPEUTICS, INC.
Vermogen: - $ op 31-07-2023
Actieve functies van Josias Fantato De Pontes
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| SIGILON THERAPEUTICS, INC. | Comptroller/Controller/Auditor | 18-02-2022 | - |
| Financieel Directeur/CFO | 18-02-2022 | - | |
| Treasurer | 18-02-2022 | - | |
| Corporate Officer/Principal | 01-11-2019 | 14-06-2021 |
Loopbaan van Josias Fantato De Pontes
Eerdere bekende functies van Josias Fantato De Pontes
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| LARIMAR THERAPEUTICS, INC. | Corporate Officer/Principal | 01-12-2017 | 31-08-2019 |
| JUNIPER PHARMACEUTICALS INC | Corporate Officer/Principal | 01-01-2016 | 01-01-2018 |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Comptroller/Controller/Auditor | - | 01-05-2007 |
| Corporate Officer/Principal | 01-05-2007 | 01-06-2015 |
Opleiding van Josias Fantato De Pontes
| The Ohio University | Masters Business Admin |
| Fundação Escola de Comércio Álvares Penteado | Undergraduate Degree |
Statistieken
Internationaal
| Verenigde Staten | 6 |
| Brazilië | 2 |
Operationeel
| Corporate Officer/Principal | 4 |
| Comptroller/Controller/Auditor | 2 |
| Director of Finance/CFO | 1 |
Sectoraal
| Health Technology | 5 |
| Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| SIGILON THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
Zafgen, Inc.
 Zafgen, Inc. BiotechnologyHealth Technology Zafgen, Inc. is a biopharmaceutical company, which engages in the development of novel therapies for patients affected by complex metabolic diseases. It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders. The firm also advancing programs for type 2 diabetes, Prader-Willi syndrome, and liver diseases. The company was founded on November 22, 2005 and is headquartered in Boston, MA. | Health Technology |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Catalent JNP, Inc.
 Catalent JNP, Inc. Pharmaceuticals: MajorHealth Technology Catalent JNP, Inc. engages in the research and development of drugs and therapeutics. It offers analytical characterization and pre-formulation testing; formulation development; and clinical manufacturing of capsules and tablets. The company was founded in December 1986 and is headquartered in Somerset, NJ. | Health Technology |
